Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as... see more

Recent & Breaking News (CSE:BETR)

BetterLife (CSE:BETR) confirms non-hallucinogenic properties of TD-0148A

Julia Kennedy  November 16, 2021

BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property

GlobeNewswire November 16, 2021

Developing Psychedelic Medicine Beyond What We Already Know!

GlobeNewswire November 5, 2021

BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain

GlobeNewswire November 4, 2021

BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference

Newsfile October 25, 2021

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

PR Newswire October 18, 2021

Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2

GlobeNewswire October 12, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

PR Newswire October 11, 2021

BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies

GlobeNewswire September 29, 2021

BetterLife files patent for treatment of cluster headaches and related disorders

John Ballem  September 27, 2021

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

GlobeNewswire September 27, 2021

BetterLife (CSE:BETR) enrolls first patient in Interferon alpha-2b COVID-19 trial in Chile

John Ballem  September 22, 2021

BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile

GlobeNewswire September 22, 2021

BetterLife to Present at the Emerging Growth Conference on September 15, 2021

GlobeNewswire September 13, 2021

BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies

GlobeNewswire September 9, 2021

BetterLife Pharma (CSE:BETR) initiates preclinical study against Delta variant

Trevor Abes  August 25, 2021

BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2

GlobeNewswire August 25, 2021

BetterLife (CSE:BETR) approved to conduct COVID-19 trial with Pontificia Universidad Católica de Chile

Julia Kennedy  July 27, 2021

BetterLife (CSE:BETR) partners with Carleton University to research treatment for chronic anxiety

Julia Kennedy  July 22, 2021

BetterLife’s (CSE:BETR) AP-003 shown to be effective against COVID-19 variants

Trevor Abes  July 15, 2021